News 10.01.2020 Zurich-Schlieren, Switzerland, January 10, 2020. Proteomedix, a swiss diagnostics company committed to advance prostate cancer care announced today that its board of directors has appointed Helge Lubenow as Chief Executive Officer effective January 1, 2020. Helge will succeed Ralph Schiess, co-founder of Proteomedix who is transitioning to a newly established...
News 27.12.2019 Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinicalstage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of Multiple Myeloma. MP0250 is...
Internal events
Event date: 11.03.2020
Date: 04.11.2020
Location: Bio-Technopark Schlieren-Zurich, Auditorium, Wagistrasse 25, 8952 Schlieren
Organized by:
- European Patent Academy
- Swiss Federal Institute of Intellectual Property
Description:
- Why can IP support my business?
- What can be patented in the Biotech area?
- How can SMEs implement an IP strategy?
The roadshow provides answers to these questions by specialists in business...
External events
Event date: 06.02.2020
TIME AND PLACE?
Thursday, 6 February 2020, 08:00 – 18:00 @ Radisson Hotel Airport, Zurich, Switzerland
WHAT IS SWISS NORDIC BIO?
Swiss Nordic Bio is an investor and partnering conference connecting leading Nordic and Swiss healthcare companies with European investors. For more information about the event please visit www.swissnordicbio.com or contact us.
WHAT IS...
News 07.12.2019 Zurich-Schlieren, Switzerland, December 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced a poster presentation at the American Society of Hematology 61st Annual Meeting in Orlando, FL, highlighting the activity of its tri-specific DARPin® drug candidate, MP0250, in patients undergoing...